Quantification of Thyroglobulin, a Low-Abundance Serum Protein, by Immunoaffinity Peptide Enrichment and Tandem Mass Spectrometry

Andrew N. Hoofnagle,1* Jessica O. Becker,1 Mark H. Wener,1 and Jay W. Heinecke2

BACKGROUND: Quantification of serum tumor markers plays an important role in determining whether patients treated for cancer require further therapy. Whereas large-scale proteomic efforts aim to identify novel tumor markers to facilitate early detection, optimization of methods for quantifying known tumor markers offers another approach to improving management of malignancies. For example, immunoassays used in clinical practice to measure established tumor markers suffer from potential interference from endogenous immunoglobulins and imperfect concordance across platforms—problems that also plague many other immunoassays. To address these important limitations, this study used peptide immunoaffinity enrichment in concert with liquid chromatography–tandem mass spectrometry (LC-MS/MS) to quantify thyroglobulin, a well-characterized tumor marker.

METHODS: We identified 3 peptides in tryptic digests of thyroglobulin that were detected at low concentrations by tandem mass spectrometry, raised polyclonal antibodies to those peptides, and used the antibodies to extract the 3 corresponding peptides from tryptic digests of human serum. We quantified each endogenous peptide using LC-MS/MS and multiple reaction monitoring with external calibrators.

RESULTS: The detection limit for endogenous thyroglobulin in serum was 2.6 μg/L (4 pmol/L). Direct comparison with immunoassay revealed good correlation ($r^2 = 0.81$).

CONCLUSIONS: Immunoaffinity peptide enrichment–tandem mass spectrometry can detect tryptic peptides of thyroglobulin at picomolar concentrations while also digesting the endogenous immunoglobulins that can potentially interfere with traditional immunoassays. Our observations suggest a general analytical strategy for using immunoaffinity isolation together with tandem mass spectrometry to quantify tumor antigens and other low-abundance proteins in human serum.

© 2008 American Association for Clinical Chemistry

There is intense interest in using proteomics to discover novel biomarkers for the diagnosis and prognosis of disease; however, validation has proved to be a major stumbling block (1). Although the final aim of biomarker discovery efforts is the development of a novel quantitative clinical assay, current immunoassay methodologies suffer from well-known limitations. Successful clinical validation of new disease markers may be hampered by these limitations when tested in diverse patient populations. Serum thyroglobulin (Tg),3 which is already used in conjunction with imaging to determine the clinical management of patients following treatment of thyroid carcinoma, represents one of the best-validated serum tumor markers in clinical chemistry (2–5). It is also an example of a biomarker whose clinical utility is hampered by limitations in analytical methods.

Several studies have meticulously characterized the problems associated with the quantification of serum thyroglobulin, problems that are shared by many other immunoassays. For example, approximately 10% of patients have antibodies to Tg that could potentially interfere with immunoassays (6–9). The prevalence of Tg autoantibodies increases to 25% in patients with differentiated thyroid carcinoma, although the reasons for this are incompletely understood (10–12). In addition, 3% of all patients have nonspecific heterophilic interfering antibodies that bind to reagent Klh, keyhole limpet hemocyanin; MRM, multiple reaction monitoring.
immunoglobulins, typically causing false-positive results in sandwich immunometric assays. Heterophilic antibody blocking reagents can reduce the number of false positives 30-fold, but a number of subjects continue to have false-positive results (13). Commercial serum thyroglobulin assays also suffer from a lack of concordance across platforms, likely owing to large variability in posttranslational modification of Tg in vivo (14–16). Even with an international reference material available, results for patient samples are often substantially different with different assays—an issue common to other immunoassays (17–19).

To test a general approach to detecting low-abundance proteins in serum that avoids the limitations inherent to immunoassays, we took advantage of the power of mass spectrometry (MS) to detect specific peptides in complex mixtures. Previous attempts to use MS to quantify low-abundance endogenous serum proteins include the direct detection of peptides from trypsin-digested serum with (20) and without (21) serum fractionation. However, only nanomolar concentrations of endogenous protein were detectable. We therefore tested a method developed by Anderson et al. (22), termed “stable isotope standards and capture by antipeptide antibodies,” that combines immunoaffinity peptide purification with tandem mass spectrometry. As a test protein, we selected thyroglobulin.

Materials and Methods

PEPTIDE ISOLATION AND IDENTIFICATION

Purified human thyroglobulin (Swiss-Prot accession no. P01266; Cortex Biochem) was digested with 3 different digestion protocols (see details in Supplemental Methods, which accompany the online version of this article at http://www.clinchem.org/content/vol54/issue10). For digestion 1, Tg was denatured with urea, reduced, alkylated, and digested with trypsin. Digestion 2 used the same conditions as digestion 1 without reduction and alkylation. Digestion 3 used the same conditions as Digestion 1 except that Tg was supplemented with normal human serum (Tg:serum protein ratio approximately 1:60). We purified the resulting peptides from each digestion using solid-phase extraction and identified them using 2 complementary techniques: a) microelectrospray ionization liquid chromatography–tandem mass spectrometry (LC-MS/MS) on a linear ion trap mass analyzer and b) off-line HPLC-plate spotting followed by matrix-assisted laser desorption ionization–tandem time of flight mass spectrometry (MALDI-TOF/TOF). Database searching was performed as described in Supplemental Methods. The peptides used below were unique in the translated nonredundant human genome database according to Blast searching performed as described in Supplemental Methods.

INTERNAL STANDARD PEPTIDE

Stable isotope–labeled internal standard peptide (VIFDANPV*AVR, where V* represents $^{13}$C$_5$$^{14}$N-labeled valine) was synthesized and analyzed for purity and amino acid content using Anaspec. We based subsequent calculations of concentration on the purity assessment and amino acid analysis. Isotopic purity of the peptide was 99.9%.

QUANTIFICATION OF INTERNATIONAL TG REFERENCE MATERIAL

After reduction and alkylation, triplicate dilution series of a certified reference preparation of Tg (BCR-457; Sigma) were digested for 2 h at 37 °C using 0.5 μg sequencing-grade modified trypsin in 0.1% RapiGest (Waters Corp.). Peptides were then lyophilized and reconstituted in 5% acetonitrile, 0.1% formic acid in water. Suspended peptides were mixed with an equal volume of isotope-labeled peptide (15 nmol/L) and analyzed using LC-MS/MS. To determine the concentration of BCR-457, we fitted data from 3 independent experiments using the relation $y = Ax^n$, which was used to calculate the dilution necessary to achieve a response of 1.0 [i.e., solving for the dilution (x) where the response (y) equals 1.0].

ANTISERUM PREPARATION

Based on the MS/MS analysis of tryptic digests of Tg (see Results), we selected 3 peptides for antisera production (VIFDANPVAVR, peptide 1; LGDQEFIK, peptide 2; and FPLGESFLVAK, peptide 3) (EZBiolab). We conjugated each peptide (2 mg) to 10 mg keyhole limpet hemocyanin (KLH) (Calbiochem) using the glutaraldehyde method. We also conjugated peptide 1 w to KLH using N-(3-dimethylaminopropyl)-N’-ethylcarbodiimide hydrochloride (EDAC) (Sigma), according to the manufacturer’s instructions. The efficiency of conjugation was >65% for each reaction, as measured by MS/MS quantification of peptide that passed through a 10-kDa MWCO Microcon filter (Millipore). The peptide–KLH conjugates were combined and used to immunize 2 New Zealand White rabbits (standard protocol; Pacific Immunology).

PEPTIDE-CONJUGATE BEADS, AFFINITY PURIFICATION OF ANTIBODY, AND ANTIPEPTIDE PARAMAGNETIC BEADS

We conjugated the peptides to BSA using the same procedures as for KLH. Peptide-BSA conjugates were then covalently bound to CNBr-activated Sepharose 4B (0.32 g) (GE Lifesciences) according to the manufacturer’s instructions. Analysis of the protein concentration of the supernatant confirmed >63% conjugate binding to the beads (Coomassie Plus; Pierce). We in-
cubated the peptide-BSA-Sepharose conjugate with 10 mL rabbit serum (16 h, 4 °C), washed the beads with PBS, and eluted the antibodies in 870-μL fractions with 200 mmol/L glycine, pH 2.80, into tubes containing 27 μL 3 mol/L Tris, pH 8.6, and 100 μL 3 mol/L KCl. Peak fractions were pooled. The yield was 2–6 mg per 10 mL rabbit serum. The affinity-purified antibody was co-

AFFINITY PURIFICATION OF THYROGLOBULIN PEPTIDES
Serum (100 μL) was diluted with 400 μL 100 mmol/L NH₄HCO₃, 0.005% Tween 20, and reduced with 5 pmol binding sites/μL paramagnetic beads (2 × 10⁹ beads/μL). Reactions resulted in 2.3 (0.12) [mean (SD)] valently bound to tosyl-activated Dynal M-280 beads.

RESULTS
SELECTING TG PEPTIDES FOR LC-MS/MS ANALYSIS
We analyzed tryptic digests of Tg with and without serum supplementation by tandem mass spectrometers interfaced with different ionization systems to determine which Tg peptides could best be detected and quantified by this approach. Data for the 15 most abundant peptides are presented in Supplemental Table 1. We immunized 2 New Zealand White rabbits with the 3 peptides that were detected most reliably by both ESI-ion trap and MALDI-TOF/TOF instruments. We included the fourth-most abundant peptide from digestion 1 (FPLGESFLVAK) rather than the third-most abundant one (SHGQDSPAVYLK), because the latter was not well recovered when Tg was digested without reduction and alkylation or in the presence of serum proteins. Rather than generating 3 individual polyclonal preparations, we separately conjugated the peptides to KLH and immunized the rabbits with the pooled conjugates. We chose the most abundant peptide across platforms and digestions (VIFDANPVA, peptide 1) as the internal standard peptide and synthesized a stable isotope-labeled peptide.

ISO TOPE DILUTION QUANTIFICATION OF THYROGLOBULIN IN THE CERTIFIED REFERENCE MATERIAL
The international certified reference material BCR-457, which is used to provide traceable commercial immunoassays, was generated in 1992 from pooled human thyroglobulin from cadaveric thyroid tissue (23). However, the concentration of thyroglobulin was quantified using the Lowry method, which has been shown to be less precise than direct detection (24). We therefore quantified the amount of thyroglobulin in the preparation by isotope dilution, using a stable isotope-labeled synthetic peptide (peptide 1). Linear dilutions of a thyroglobulin–internal standard peptide mixture were digested, and the peptide mixture was supplemented with known amounts of internal standard peptide (Fig. 1). This approach indicated that the concentration of thyroglobulin in BCR-457 was 317 (7) mg/L (n = 3), which is very similar to the previously assigned value of 324 (18) mg/L.

OPTIMIZATION OF DIGESTION FOR QUANTIFICATION BY LC-MS/MS
Thyroglobulin is a large macromolecule consisting of 2 330-kDa monomers. We first attempted to detect Tg...
after using size-exclusion chromatography or ultrafiltration to separate it from other serum proteins before trypsin digestion. Enrichment of Tg using size separation was ineffective, resulting in a limit of detection more than 1000-fold higher than the clinically desired limit of detection. We therefore optimized the digestion of whole serum for the immunoaffinity enrichment of Tg peptides. One important source of variability in proteomic analyses is partial proteolytic digestion of complex biological material. High concentrations of chaotropic salts are commonly used to denature proteins and help facilitate more complete tryptic digestion (25). Although the denaturants are generally removed by solid-phase extraction after digestion, their use could increase variability owing to differential recovery of peptide and additional specimen manipulation. As an alternate approach, we tested different concentrations of Tween 20, a nonionic detergent that helps denature proteins and may also improve stringency in the immunoaffinity purification step. Reduction and alkylation of 20% serum made the solution cloudy, but adding trypsin always cleared it when Tween 20 was present (0.005%, wt/vol). To promote proteolysis, we therefore included Tween rather than chaotropic salts in the serum digestion step. Sequencing-grade modified trypsin, which is usually used at much higher concentrations than in our studies, is expensive. We therefore investigated other commercial preparations of modified trypsin at 135–17000 units of enzyme-specific activity per sample. However, only sequencing-grade trypsin was able to clarify the 10 human samples tested. Importantly, at the relatively low concentrations of trypsin used, it is unlikely that these clarified samples were completely digested.

OPTIMIZING TG QUANTIFICATION BY IMMUNOAFFINITY PEPTIDE ENRICHMENT AND LC-MS/MS

We incubated tryptic digests of reduced and alkylated serum with anti-Tg peptide antibodies bound to paramagnetic beads. After washing, bound peptides were eluted from the beads and bound to a C18 trapping column. The column was then washed, and the peptides were eluted and resolved on an analytical column with an acetonitrile gradient. Fig. 2 illustrates the ion current chromatogram for the internal standard and endogenous peptide MRM transitions. Peptides 1 and 2 elute earlier than peptide 3 and have a narrower peak width. Tandem mass spectra were collected in parallel with the MRM transitions, using the linear ion trap of the 4000 Q-TRAP mass spectrometer (Fig. 2, right panels). Interpretable MS/MS spectra were acquired for each peptide in samples containing as little as 100 μg/L endogenous Tg.

To determine which of the 3 peptides performed best in the assay, we tested human serum containing 319 μg/L endogenous thyroglobulin diluted serially with serum lacking Tg. The 3 peptides exhibited different behaviors (Fig. 3). Each of the peptides had a marked background signal resulting from peptide that populated antigen-binding sites after affinity purification of the antibody. Peptide 2 performed best, however, with a minimal detectable concentration of 3.9 μg/L in this experiment. Peptide 1 had a higher background signal and had a minimal detectable concentration of 35 μg/L. The peak area of peptide 3 demonstrated greater variability in its signal-to-noise ratio, and the minimal detectable concentration of Tg was 319 μg/L. After digestion, we added internal standard peptide to control for variability in the volume of immunoglobulin-coated beads added, variability in sample volume injected, and mass spectrometer performance. After normalization to the internal standard peptide, the responses of peptides 1 and 2 had characteristics similar to their respective ion current peak areas, but the response of peptide 3 was still more erratic (Fig. 3).

Because of its superior performance in the LC-ESI-MS/MS analysis, we used peptide 2 to quantify Tg in subsequent human serum specimens. We calculated peptide response as the peak area of analyte divided by the peak area of the surrogate internal standard isotope-labeled peptide, which was chemically identical...
Fig. 2. Chromatography and tandem mass spectrometry of immunoaffinity-purified thyroglobulin peptides. Immunoaffinity-purified peptides were first loaded onto a peptide-trapping column before being resolved with a C18 analytical column, ionized using micro-ESI, and analyzed using MRM. Elution profiles of peptides purified from a digest of human serum are shown (left panels). Fragment ion spectra were collected in the linear ion trap of the mass spectrometer at the same time as MRM data. They are shown for each peptide (right panels). V*, stable isotope–labeled valine residue.
to peptide 1 rather than peptide 2. We analyzed external human serum calibrators (0, 2, 5, and 20 µg/L) in parallel with other specimens. Performance characteristics of the assay are presented in Table 1. Intraassay imprecision was 13.7% at 22.3 µg/L, 22.5% at 5.5 µg/L, and 21.4% at 3.8 µg/L (6 pmol/L). Interassay precision was 17.4% at 6.0 µg/L. The lower limit of detection, defined as the concentration corresponding to mean + 2 SDs of the zero calibrator, was 2.6 µg/L (4 pmol/L), which is equivalent to 0.8 femtomoles of peptide injected on column. At 3.8 µg/L, the mean signal-to-noise ratio was 13.8. Recovery of Tg added at 21.6 µg/L to 5 different human serum samples lacking Tg ranged from 85.0% to 99.6% [mean (SD), 93.0% (5.4%)]. Calculated using peak area, carryover was 0.8% (0.8%).

**Table 1. Performance characteristics.**

<table>
<thead>
<tr>
<th>Tg concentration, µg/L</th>
<th>Result</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intraassay imprecision</td>
<td>22.3</td>
</tr>
<tr>
<td>5.5</td>
<td>22.5%</td>
</tr>
<tr>
<td>3.8</td>
<td>21.4%</td>
</tr>
<tr>
<td>Interassay imprecision</td>
<td>6.0</td>
</tr>
<tr>
<td>Lower limit of detection</td>
<td>—</td>
</tr>
<tr>
<td>2.6 µg/L</td>
<td></td>
</tr>
<tr>
<td>Signal-to-noise ratio</td>
<td>3.8</td>
</tr>
<tr>
<td>Recovery</td>
<td>21.6</td>
</tr>
<tr>
<td>85.0%–99.6%</td>
<td></td>
</tr>
<tr>
<td>Carryover</td>
<td>—</td>
</tr>
<tr>
<td>0.8%</td>
<td></td>
</tr>
</tbody>
</table>

**CORRELATION OF TG QUANTIFICATION BY IMMUNOASSAY AND MASS SPECTROMETRY**

To determine how well the results of the LC-ESI-MS/MS assay correlated with those from a clinical immunoassay for Tg, we analyzed 33 samples previously quantified by the Beckman Access 2 assay. The range of Tg concentrations determined by the immunoassay was 3.0–33.2 µg/L. The Deming regression equation had a slope (95% CI) of 1.03 (0.85–1.22) and an inter-
cept of $-1.84$ ($-4.93$ to $1.26$). The correlation ($r^2$) was 0.81, and the standard error of the residuals ($S_{YX}$) was 3.91 (Fig. 4).

**Discussion**

Serum Tg has long been a thorn in the side of clinical tumor marker immunoassays because of its low concentration and common interferences $(8, 10, 11, 13, 26)$. Therefore, we used Tg as the analyte in this study, which tested peptide immunoaffinity purification/mass spectrometry to measure an endogenous, clinically important low-abundance protein in human serum, a complex biological matrix. We were able to reliably detect $2.6 \mu$g/L (4 pmol/L) of endogenous Tg, which is well within the range of $2.3$–$139 \mu$g/L observed in euthyroid subjects $(27)$. Our results demonstrate a marked improvement in the limit of detection over previously published MS approaches. For example, MS has been used to quantify peptides derived from tryptic digests of proteins in human serum, including Zn-$\alpha$2 glycoprotein $(21)$, which was detected with a limit of detection of $90 \text{nmol/L}$ (approximately 3 mg/L). A study that fractionated serum to quantify C-reactive protein had a limit of detection of $7 \text{nmol/L}$ $(20)$. Whiteaker et al. $(28)$ used stable isotope standards and capture by antipeptide antibodies to detect endogenous fibulin-2 in mouse plasma with a limit of detection of $380 \text{pmol/L}$.

Quantifying Tg by peptide capture and LC-MS/MS performed well in comparison with the immunoassay we used, even in the low picomolar range in serum. Peptide immunoaffinity purification/mass spectrometry $(22)$ has potential advantages over immunoassays. For example, it is in principle straightforward to multiplex the assay by including additional antipeptide antibodies and isotope-labeled peptides. Moreover, because of the power of MS/MS and MRM to detect peptides in complex mixtures, it is not necessary to develop highly specific antibodies that react only with the peptides or proteins of interest. Indeed, in this experiment, the rabbit antiserum used contained antibodies directed against all 3 Tg peptides. Finally, because our protocol digests endogenous immunoglobulins that can potentially interfere with immunometric measurements, it should avoid many potential limitations of conventional immunoassays $(8, 13, 26)$.

The peptide immunoaffinity enrichment strategy offers other advantages. For example, many investigators have attempted to decrease the limit of detection of MS analysis by immunodepleting abundant proteins. However, removing immunoglobulins could also deplete the analyte of interest in patients with autoantibodies. It is well known that many proteins strongly interact with albumin $(29)$, so removal of this single-most-abundant serum protein could also produce erroneously low measurements. By directly detecting analyte in reference to a stable isotope-labeled internal standard peptide, mass spectrometry has the advantage of being more easily standardized across laboratories $(18)$, provided a reference preparation is available, as is the case for Tg $(23)$. The improvements in low-abundance serum protein quantification presented here could help provide an alternative diagnostic approach to the methods that are traditionally plagued by interference and lack of standardization $(7, 19, 26)$.

It is important to note several limitations of our studies. For example, 4 $\mu$g affinity purified polyclonal

---

**Fig. 4. Correlation of Tg quantification by immunoaffinity enrichment–LC-MS/MS and an immunoassay.**

Results using immunoaffinity purification of peptides from tryptic digests with external calibration were compared with a standard clinical immunoassay for Tg in serum (left). The Deming regression equation (Analyze-It) is shown with the Pearson correlation coefficient $(r^2)$. The residuals of each data point from the regression line are also shown (right) with the standard error of the residuals ($S_{YX}$). The estimate of the true value was calculated using the ratio of the SD of each method using Analyze-It.
antibody was required for each sample and calibrator, which is 2–3 orders of magnitude more than what is commonly used in sandwich ELISA protocols (30). Additionally, small amounts of the peptides were non-covalently associated with the albumin-peptide conjugate and bound directly to the CNBr-activated beads used for affinity purification. Those peptides were slowly hydrolyzed from the solid phase, which led to a background signal. As a result, only peptide 2 of the 3 peptides tested allowed sufficient detection of endogenous thyroglobulin, owing to its lower background signal. In addition, it appears that peptide 3 elicited a weaker antibody response than the other peptides, as evidenced by its relatively high limit of detection. Using other strategies to generate affinity-purified, high-avidity polyclonal antibodies might alleviate these problems, which could also be avoided by using monoclonal antibodies that do not require affinity purification. Even in the face of difficulties with 2 of the 3 peptides, however, we were able to demonstrate good intraassay imprecision for peptide 2 at a concentration of 3.8 μg/L (6 pmol/L) in human serum.

Despite these limitations, this peptide affinity isolation strategy offers major advantages. It is relatively straightforward to generate polyclonal antibodies to candidate biomarkers, and cross-reacting antibodies can be used. Also, an internal standard automatically corrects for differences in analyte recovery and detection during sample work-up and analysis.

In conclusion, we employed Tg, a protein that is present at low concentrations in serum and commonly associated with interfering antibodies, to demonstrate the feasibility of using peptide affinity capture and MS/MS to quantify a well-characterized tumor marker. Further studies of this approach have the potential to provide new benchmark methods for quantifying proteins in clinical assays.

Author Contributions: All authors confirmed they have contributed to the intellectual content of this paper and have met the following 3 requirements: (a) significant contributions to the conception and design, acquisition of data, or analysis and interpretation of data; (b) drafting or revising the article for intellectual content; and (c) final approval of the published article.

Authors’ Disclosures of Potential Conflicts of Interest: No authors declared any potential conflicts of interest.

Authors’ Disclaimers: None declared.

Role of Sponsor: The funding organizations played no role in the design of study, choice of enrolled patients, review and interpretation of data, preparation or approval of manuscript.

Acknowledgments: The authors thank Matthew Champion, Jeff Whiteaker, and Mike MacCoss for helpful discussions.

References

9. Ericsson UB, Christensen SB, Thorll JI. A High Prevalence of Thyroglobulin Autoantibodies in
Quantification of Low-Abundance Proteins by LC-MS/MS


